Innovation Pharma to begin patient screening for phase 1 trial of oral brilacidin to treat ulcerative colitis

Innovation Pharmaceuticals, a clinical stage pharmaceutical company, announced that patient screening for its phase 1 trial to investigate the use in healthy volunteers of delayed release tablets for colonic delivery of oral Brilacidin for treating ulcerative colitis, a chronic form of inflammatory bowel disease (IBD), is expected to commence in early January. Approximately two weeks ago, the United Kingdom’s Medicines and Healthcare products Regulatory Agency granted the Company approval to start the phase 1 trial. Along with assessing the safety, toleration, and pharmacokinetics of oral Brilacidin, the study will evaluate the delivery of oral Brilacidin directly to the colon by utilising advanced delayed-release drug delivery technology developed by the Company’s formulation partner. “The study is expected to be a quick one, with dosing completed within several weeks of commencement, and, if successful, would translate into numerous potential positive outcomes for the company,” noted Leo Ehrlich, chief executive officer at Innovation Pharmaceuticals. “We are optimistic about the safety and efficacy profile of Brilacidin in IBD based on our prior clinical trial in ulcerative proctitis/ulcerative proctosigmoiditis, and are further encouraged that our out-licensing partner in this indication is planning to start trials mid-year 2020. Now the key to differentiation and really catching the attention of big pharma for the opportunity is efficient delivery of the drug directly into the colon.” Ehrlich continued: “Given the industry buzz around the recent IPOs of Galera Therapeutics and Monopar Therapeutics, each with late-stage drug candidates targeting Oral Mucositis, we feel confident about the competitive positioning and commercial prospects of oral rinse Brilacidin as a preventative OM drug candidate and the considerable value it can bring to our company. The investment community seems to be waking up to the large unmet need in this area. We anticipate an active partnering process, with meetings scheduled with pharmaceutical companies interested in Brilacidin-OM during the 2020 J.P. Morgan Healthcare conference this January in San Francisco. A licensing deal for the Brilacidin-OM asset would bring significant upside for our shareholders.” In other news: The Company would like to inform shareholders that Arthur P. Bertolino, MD, PhD, MBA, has resigned from his positions as director, and president and chief medical officer. Dr. Bertolino and the company have discussed the possibility for Dr. Bertolino continuing to serve as a consultant to the Company. The Company will begin interviewing new candidates for the position of chief medical officer in January.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!